Zydus Lifesciences Limited

Zydus Lifesciences Limited (India) holds 154 active US FDA Type II Drug Master Files and 3 inactive, has DMF or CEP filings on record for 40 active ingredients and is linked to 6 FDA-registered manufacturing sites. 50 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Zydus Lifesciences Limited: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/zydus-lifesciences-limited

Overview

Zydus Lifesciences Limited, formerly known as Cadila Healthcare, is a leading Indian pharmaceutical company engaged in the discovery, development, and manufacture of a wide range of healthcare products. The company is known for its strong presence in the generics market and is committed to delivering affordable and innovative medicines globally.

Core services & business areas

Pharmaceutical ManufacturingResearch and DevelopmentRegulatory Affairs

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Zydus Lifesciences Limited holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Zydus Lifesciences Limited holds 154 active (157 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • SACUBITRIL AND VALSARTANActive2026-08-29
  • RESMETIROMActive2026-04-29
  • SITAGLIPTIN HYDROCHLORIDEActive2026-03-31
  • EMPAGLIFLOZINActive2026-03-31
  • DONEPEZIL HYDROCHLORIDE USP (PROCESS-II)Active2025-12-30
  • DEUCRAVACITINIBActive2025-12-30
  • BENZGALANTAMINE GLUCONATEActive2025-12-26
  • IVACAFTORActive2025-12-19
  • ESOMEPRAZOLE MAGNESIUM DIHYDRATE USP (PROCESS-III)Active2025-12-17
  • SAROGLITAZAR MAGNESIUMActive2025-10-02
  • VISMODEGIBActive2025-07-02
  • TOLVAPTANActive2025-06-27
  • DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE USPActive2024-12-31
  • SUVOREXANTActive2024-12-30
  • GABAPENTIN ENACARBILActive2024-12-30
  • LETROZOLE USPActive2024-11-18
  • VORTIOXETINE HYDROBROMIDE (PROCESS-2)Active2024-11-07
  • EXEMESTANE USPActive2023-12-30
  • CALCIUM GLUCONATE MONOHYDRATE USPActive2023-10-09
  • LUMATEPERONE TOSYLATEActive2023-09-21
  • VOXELOTORActive2023-04-08
  • VALACYCLOVIR HYDROCHLORIDE USPActive2022-12-31
  • MIDODRINE HYDROCHLORIDE USPActive2022-12-30
  • VILOXAZINE HYDROCHLORIDEActive2022-12-27
  • LABETALOL HYDROCHLORIDE USPActive2022-12-26
  • OSELTAMIVIR PHOSPHATE USPActive2022-11-24
  • NATEGLINIDE USPActive2022-09-20
  • BENAZEPRIL HYDROCHLORIDE USPActive2022-05-31
  • MEMANTINE HYDROCHLORIDE USPActive2021-12-10
  • APALUTAMIDEActive2021-09-09
  • CLOPIDOGREL BISULFATE USP (PROCESS-III)Active2021-06-30
  • CLOPIDOGREL BISULFATE USP (PROCESS-II)Active2021-06-24
  • LETERMOVIRActive2021-06-19
  • RIFAXIMIN (PROCESS-II)Active2020-12-25
  • ALBENDAZOLE USPActive2020-11-28
  • DIROXIMEL FUMARATEActive2020-11-26
  • ASPIRIN USPActive2020-10-29
  • RIFAXIMIN (PROCESS-I)Active2020-10-29
  • PIMAVANSERIN TARTRATEActive2020-07-28
  • ELTROMBOPAG OLAMINEActive2020-07-07
  • TIZANIDINE HYDROCHLORIDE USPActive2020-06-23
  • VALSARTAN USPActive2020-04-30
  • BRIVARACETAMActive2019-12-31
  • ENZALUTAMIDE (PROCESS II)Active2019-12-31
  • IMATINIB MESYLATE (PROCESS II)Active2019-12-31
  • DARUNAVIRActive2019-05-29
  • CLOPIDOGREL BISULFATE USPActive2019-04-24
  • COLESTIPOL HYDROCHLORIDE USPActive2019-04-01
  • CHLORTHALIDONE USPActive2019-02-28
  • BREXPIPRAZOLEActive2018-12-29

Showing the 50 most relevant of 157 Drug Master Files (active first). The full list is in the FDA DMF list.

Registered manufacturing sites (6)

Physical sites registered with the US FDA and resolved to Zydus Lifesciences Limited, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

50 FDA enforcement records linked to this company.

  • warning_letter2026-06-02

    FDA Warning Letter (drug product)

  • 4832026-05-05

    Investigations of discrepancies, failures

  • 4832026-05-05

    Floors, walls, ceiling surfaces

  • 4832026-05-05

    Computer control of master formula records

  • 4832026-05-05

    Procedures for sterile drug products

  • 4832026-05-05

    Validation lacking for sterile drug products

  • 4832026-05-05

    Absence of Written Procedures

  • 4832026-05-05

    In-process materials characteristics testing

  • warning_letter2024-08-29

    FDA Warning Letter (drug product)

  • 4832024-04-23

    Cleaning SOPs/instructions

  • 4832024-04-23

    Absence of Written Procedures

  • 4832024-04-23

    Training , Education , Experience overall

  • 4832024-04-23

    Investigations of discrepancies, failures

  • 4832024-04-23

    Following/documenting laboratory controls

  • 4832024-04-23

    Procedures for sterile drug products

  • 4832024-04-23

    Computer control of master formula records

  • 4832024-04-23

    Cleaning / Sanitizing / Maintenance

  • 4832024-04-23

    Environmental Monitoring System

  • 4832024-04-23

    Validation lacking for sterile drug products

  • 4832024-03-27

    Cleaning / Sanitizing / Maintenance

  • 4832024-03-27

    Procedures for sterile drug products

  • 4832024-03-27

    Environmental Monitoring System

  • 4832024-03-27

    Buildings not maintained in good state of repair

  • 4832022-08-05

    Investigations of discrepancies, failures

  • 4832022-08-05

    Procedures To Be in Writing

  • 4832022-08-05

    Absence of Written Procedures

  • 4832022-08-05

    Establishment of time limitations

  • warning_letter2019-10-29

    FDA Warning Letter (drug product)

  • 4832019-05-03

    Scientifically sound laboratory controls

  • 4832019-05-03

    Cleaning / Sanitizing / Maintenance

  • 4832019-05-03

    Procedures not in writing, fully followed

  • 4832019-05-03

    Investigations of discrepancies, failures

  • 4832019-05-03

    Environmental Monitoring System

  • 4832019-05-03

    Air Supply

  • 4832019-05-03

    Validation lacking for sterile drug products

  • 4832019-05-03

    Complete instructions, procedures, specifications et. al.

  • 4832019-05-03

    Procedures for sterile drug products

  • 4832019-05-03

    Cleaning System

  • 4832019-05-03

    In-process materials specifications

  • 4832019-05-03

    Backup file not maintained

  • 4832019-05-03

    Air filtration system lacking in production area

  • 4832019-05-03

    Absence of Written Procedures

  • warning_letter2015-12-23

    FDA Warning Letter (drug product)

  • warning_letter2015-12-23

    FDA Warning Letter (drug product)

  • 4832015-05-23

    Testing and release for distribution

  • 4832015-05-23

    Complete instructions, procedures, specifications et. al.

  • 4832015-05-23

    Deviations from laboratory control requirements

  • 4832015-05-23

    Written procedures not established/followed

  • 4832015-05-23

    Calibration - at intervals, written program, remedial action

  • 4832015-05-23

    Absence of Written Procedures

For suppliers

Is this Zydus Lifesciences Limited?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.